CN106852144B - 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物 - Google Patents

5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物 Download PDF

Info

Publication number
CN106852144B
CN106852144B CN201580054496.3A CN201580054496A CN106852144B CN 106852144 B CN106852144 B CN 106852144B CN 201580054496 A CN201580054496 A CN 201580054496A CN 106852144 B CN106852144 B CN 106852144B
Authority
CN
China
Prior art keywords
compound
rsv
formula
salt
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580054496.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106852144A (zh
Inventor
S·F·亨特
S·T·奥尼恩斯
V·舍伯金
E·A·F·福代斯
P·J·穆雷
D·W·布鲁克斯
伊藤和浩
P·斯特朗
M·S·科茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poole & Co Ltd
Original Assignee
Poole & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poole & Co Ltd filed Critical Poole & Co Ltd
Publication of CN106852144A publication Critical patent/CN106852144A/zh
Application granted granted Critical
Publication of CN106852144B publication Critical patent/CN106852144B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580054496.3A 2014-10-10 2015-10-08 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物 Active CN106852144B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
EP14188494.0 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Publications (2)

Publication Number Publication Date
CN106852144A CN106852144A (zh) 2017-06-13
CN106852144B true CN106852144B (zh) 2019-08-30

Family

ID=51842340

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580054496.3A Active CN106852144B (zh) 2014-10-10 2015-10-08 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物

Country Status (13)

Country Link
US (6) US9732098B2 (OSRAM)
EP (2) EP3204389B1 (OSRAM)
JP (2) JP2017531039A (OSRAM)
KR (1) KR20170058921A (OSRAM)
CN (1) CN106852144B (OSRAM)
AU (1) AU2015329789B2 (OSRAM)
BR (1) BR112017005104B1 (OSRAM)
CA (1) CA2957868C (OSRAM)
EA (1) EA201790796A8 (OSRAM)
IL (1) IL250823A0 (OSRAM)
MX (1) MX2017004652A (OSRAM)
SG (1) SG11201701184WA (OSRAM)
WO (2) WO2016055792A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957868C (en) * 2014-10-10 2023-02-28 Pulmocide Limited Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
US10160772B2 (en) 2014-12-18 2018-12-25 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
PL3324977T3 (pl) 2015-07-22 2022-11-14 Enanta Pharmaceuticals, Inc. Pochodne benzodiazepiny jako inhibitory rsv
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
CA3006488A1 (en) * 2016-02-03 2017-08-10 Janssen Sciences Ireland Uc Combination products for the treatment of rsv
US10626126B2 (en) * 2016-04-08 2020-04-21 Pulmocide Limited Compounds
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
KR102634720B1 (ko) 2017-11-13 2024-02-06 이난타 파마슈티칼스, 인코포레이티드 벤조디아제핀-2-온 및 벤조아제핀-2-온 유도체의 분할 방법
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
WO2020210246A1 (en) * 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2021066922A1 (en) 2019-10-04 2021-04-08 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005842A1 (en) * 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
EE200100558A (et) 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
US20110052643A1 (en) * 2008-01-07 2011-03-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
PL2488486T3 (pl) 2009-10-13 2020-01-31 Ligand Pharmaceuticals Inc. Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
BR112017002332A2 (pt) 2014-08-05 2017-11-21 Alios Biopharma Inc terapia de combinação para o tratamento de um paramixovírus
CA2957868C (en) * 2014-10-10 2023-02-28 Pulmocide Limited Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
CA3006488A1 (en) 2016-02-03 2017-08-10 Janssen Sciences Ireland Uc Combination products for the treatment of rsv
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005842A1 (en) * 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor;Hui Xiong,等;《Bioorganic & Medicinal Chemistry Letters》;20131016;第23卷(第24期);第6789-6793页 *

Also Published As

Publication number Publication date
JP2017531039A (ja) 2017-10-19
CA2957868C (en) 2023-02-28
US10472375B2 (en) 2019-11-12
US20190202841A1 (en) 2019-07-04
US20170355717A1 (en) 2017-12-14
US9926335B2 (en) 2018-03-27
CN106852144A (zh) 2017-06-13
BR112017005104B1 (pt) 2022-08-23
WO2016055792A1 (en) 2016-04-14
JP6675407B2 (ja) 2020-04-01
US10273249B2 (en) 2019-04-30
KR20170058921A (ko) 2017-05-29
EP3204388A1 (en) 2017-08-16
WO2016055791A1 (en) 2016-04-14
AU2015329789B2 (en) 2019-09-26
US20170305935A1 (en) 2017-10-26
JP2017531038A (ja) 2017-10-19
EP3204389B1 (en) 2019-06-26
MX2017004652A (es) 2017-06-19
EA201790796A1 (ru) 2017-09-29
US20170190718A1 (en) 2017-07-06
US20180179228A1 (en) 2018-06-28
BR112017005104A2 (pt) 2017-12-05
US10189863B2 (en) 2019-01-29
EA201790796A8 (ru) 2018-10-31
CA2957868A1 (en) 2016-04-14
SG11201701184WA (en) 2017-03-30
IL250823A0 (en) 2017-04-30
EP3204388B1 (en) 2018-12-12
US20180319820A1 (en) 2018-11-08
EP3204389A1 (en) 2017-08-16
AU2015329789A1 (en) 2017-03-09
US9732098B2 (en) 2017-08-15
US10035810B2 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CN106852144B (zh) 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物
US10626126B2 (en) Compounds
EP3233867B1 (en) 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections
EP2776416B1 (en) Pharmaceutical compounds
TWI515193B (zh) 用於治療呼吸道融合病毒感染之化合物
JP2022507118A (ja) 呼吸器疾患の処置のための化合物及び組成物
AU2022353486A1 (en) Pharmaceutical composition containing triazine derivative
CN101583614B (zh) 用于治疗呼吸道合胞体病毒感染的多环试剂
HK1242318B (en) Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
HK1242318A1 (en) Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
WO2025214429A1 (zh) 二氨基嘧啶化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: S*F*Hunt

Inventor after: S*T*O'Neills

Inventor after: V.Sheberkin

Inventor after: E*A*F*Fudes

Inventor after: P.J.Murray

Inventor after: D.W Brooks

Inventor after: Itoh Kazuhiro

Inventor after: P.Strong

Inventor after: M*S*Coates

Inventor before: S*F*Hunt

Inventor before: S*T*O'Neills

Inventor before: V.Sheberkin

Inventor before: E*A*F*Fudes

Inventor before: P.J.Murray

Inventor before: D.W Brooks

Inventor before: Itoh Kazuhiro

Inventor before: P.Strong

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant